capecitabine has been researched along with apatinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, JQ; Jiang, RX; Li, YH; Qian, F; Tong, L; Wang, JG; Wang, XH; Wang, YW; Xiao, L; Xing, SS; Zhang, GJ; Zhao, YL; Zhou, Y | 1 |
| Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y | 1 |
| Bao, D; Chen, Z; Hu, J; Ji, J; Li, D; Li, X; Liu, S; Pang, Y; Qian, Y; Shi, M; Wang, H; Xu, L; Xu, X; Yi, C; Zhang, X; Zhou, Y | 1 |
| Cai, XY; Chen, QY; Chen, ZB; Fang, WF; Hu, PL; Hu, WH; Li, XY; Li, YJ; Li, ZM; Lin, MZ; Liu, ZG; Mai, HQ; Peng, JY; Tang, LQ; Wang, XC; Xia, LP; Yang, YP; Yu, QW; Zhang, B; Zhao, C; Zhou, H; Zhou, J | 1 |
2 trial(s) available for capecitabine and apatinib
| Article | Year |
|---|---|
Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prospective Studies; Pyridines; Treatment Outcome | 2022 |
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Topics: Capecitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prospective Studies | 2023 |
2 other study(ies) available for capecitabine and apatinib
| Article | Year |
|---|---|
Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Pyridines; Retreatment; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pyridines; Retrospective Studies; Tegafur | 2021 |